nitazoxanide has been researched along with paromomycin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Adagu, IS; Berry, NG; Lilian Low, AC; Moores, SL; Rossignol, JF; Row, E; Stachulski, AV; Warhurst, DC | 1 |
| Chong, CR; Downey, AS; Graczyk, TK; Sullivan, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blagburn, BL; Boykin, DW; Drain, KL; Kinard, RG; Land, TM; Lindsay, DS; Moore, PH; Patrick, DA; Tidwell, RR | 1 |
| Barchiesi, F; Burzacchini, F; Cirioni, O; Dini, M; Giacometti, A; Scalise, G | 1 |
| Vdovenko, AA; Williams, JE | 1 |
| Agnamey, P; Ballet, JJ; Brasseur, P; Favennec, L; Leméteil, D; Li, X; Rossignol, JF | 1 |
| Baishanbo, A; Ballet, JJ; Duclos, C; Favennec, L; François, A; Gargala, G; Rossignol, JF | 1 |
| Al-Malki, JS; Sanad, MM | 1 |
| Cabada, MM; Pantenburg, B; White, AC | 1 |
| Rossignol, JF | 1 |
| Ayuo, PO | 1 |
| Acikgoz, Y; Bek, K; Genc, G; Hokelek, M; Ozkaya, O; Sensoy, SG | 1 |
| Kelly, P | 1 |
| Dauby, N; Dupont, E; Levy, J; Menotti, J; Moens, C; Robberecht, F; Talabani, H; van Gool, T; Vandenberg, O | 1 |
| Abdella, OH; Aboshiesha, GA; Abu-Hashim, AH; El-Bader, MM; El-Shemy, AS; Hussien, SM; Taha, MA | 1 |
| Almirall, P; Ballesteros, J; Escobedo, AA; González-Fraile, E | 1 |
| Liu, M; Wang, D; Wu, X; Yin, J; Zhang, D; Zhang, Y; Zhu, G | 1 |
6 review(s) available for nitazoxanide and paromomycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of cryptosporidiosis.
Topics: AIDS-Related Opportunistic Infections; Animals; Antiretroviral Therapy, Highly Active; Azithromycin; Biliary Tract Diseases; Coccidiostats; Cryptosporidiosis; Humans; Immunocompromised Host; Nitro Compounds; Paromomycin; Rifamycins; Rifaximin; Thiazoles | 2009 |
Human cryptosporidiosis: a review.
Topics: Amebicides; Animals; Anti-Bacterial Agents; Antiparasitic Agents; Classification; Coccidiostats; Cryptosporidiosis; HIV Infections; Humans; Kenya; Nitro Compounds; Paromomycin; Prognosis; Spiramycin; Thiazoles | 2009 |
Cryptosporidiosis: a rare and severe infection in a pediatric renal transplant recipient.
Topics: Child; Coccidiostats; Cryptosporidiosis; Drug Therapy, Combination; Humans; Kidney Transplantation; Male; Nitro Compounds; Paromomycin; Postoperative Complications; Spiramycin; Thiazoles | 2012 |
Treatment and prevention of cryptosporidiosis: what options are there for a country like Zambia?
Topics: Antiprotozoal Agents; Cryptosporidiosis; Cryptosporidium; Diarrhea; Drinking Water; HIV Infections; Humans; Immunocompromised Host; Nitro Compounds; Paromomycin; Thiazoles; Water Purification; Zambia | 2011 |
Efficacy of 5-nitroimidazole compounds for giardiasis in Cuban children: systematic review and meta-analysis.
Topics: Antiprotozoal Agents; Benzimidazoles; Child; Chloroquine; Cuba; Giardiasis; Humans; Nitro Compounds; Nitroimidazoles; Paromomycin; Randomized Controlled Trials as Topic; Thiazoles; Tinidazole; Treatment Outcome | 2019 |
12 other study(ies) available for nitazoxanide and paromomycin
| Article | Year |
|---|---|
Identification of isoflavone derivatives as effective anticryptosporidial agents in vitro and in vivo.
Topics: Animals; Cattle; Cell Line, Tumor; Coccidiostats; Cryptosporidiosis; Cryptosporidium parvum; Female; Genistein; Gerbillinae; Humans; Immunocompromised Host; Isoflavones; Male; Structure-Activity Relationship | 2006 |
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
Topics: Animals; Animals, Newborn; Antiprotozoal Agents; Cell Line; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Pyrvinium Compounds; Treatment Outcome | 2008 |
Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model.
Topics: Animals; Animals, Newborn; Antiprotozoal Agents; Cryptosporidiosis; Dose-Response Relationship, Drug; Mice; Mice, Inbred ICR; Nitro Compounds; Paromomycin; Thiazoles | 1998 |
Efficacy of treatment with paromomycin, azithromycin, and nitazoxanide in a patient with disseminated cryptosporidiosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Azithromycin; Cryptosporidiosis; Cryptosporidium; Drug Therapy, Combination; Feces; Female; Humans; Nitro Compounds; Paromomycin; Thiazoles; Treatment Outcome | 1999 |
Blastocystis hominis: neutral red supravital staining and its application to in vitro drug sensitivity testing.
Topics: Amebicides; Animals; Blastocystis hominis; Chloroquine; Coloring Agents; Humans; Metronidazole; Neutral Red; Nitro Compounds; Parasitic Sensitivity Tests; Paromomycin; Quinacrine; Staining and Labeling; Sulfamethoxazole; Tetracycline; Thiazoles; Trimethoprim | 2000 |
Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model.
Topics: Adenosine; Animals; Antiprotozoal Agents; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Feces; Immunocompromised Host; Male; Nitro Compounds; Parasite Egg Count; Paromomycin; Rats; Rats, Sprague-Dawley; Thiazoles | 2003 |
Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model.
Topics: Amebicides; Animals; Antiprotozoal Agents; Biliary Tract Diseases; Cattle; Cryptosporidiosis; Cryptosporidium parvum; Dexamethasone; Feces; Gallbladder; Gerbillinae; Ileum; Immunosuppression Therapy; Immunosuppressive Agents; Nitro Compounds; Paromomycin; Thiazoles | 2006 |
Immunochemotherapy for cryptosporidiosis in immunosuppressed mouse model.
Topics: Animals; Antiprotozoal Agents; Cryptosporidiosis; Disease Models, Animal; Drug Therapy, Combination; Humans; Immunocompromised Host; Immunotherapy; Interferon-gamma; Life Cycle Stages; Mice; Nitro Compounds; Oocysts; Parasite Egg Count; Paromomycin; Random Allocation; Thiazoles; Time Factors; Treatment Outcome | 2007 |
Cryptosporidium and Giardia: treatment options and prospects for new drugs.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antiparasitic Agents; Antiretroviral Therapy, Highly Active; Azithromycin; Benzimidazoles; Cryptosporidiosis; Giardia lamblia; Giardiasis; Humans; Nitro Compounds; Nitroimidazoles; Paromomycin; Roxithromycin; Thiazoles | 2010 |
Management of a Cryptosporidium hominis outbreak in a day-care center.
Topics: Animals; Antiparasitic Agents; Belgium; Child Day Care Centers; Child, Preschool; Cryptosporidiosis; Cryptosporidium; Diarrhea; Disease Outbreaks; Feces; Female; Humans; Hygiene; Infant; Infection Control; Male; Nitro Compounds; Paromomycin; Polymerase Chain Reaction; Thiazoles | 2012 |
Comparative study between the effect of nitazoxanide and paromomycine in treatment of cryptosporidiosis in hospitalized children.
Topics: Animals; Child, Preschool; Cryptosporidiosis; Female; Hospitalization; Humans; Infant; Male; Nitro Compounds; Paromomycin; Rural Population; Thiazoles; Urban Population | 2013 |
Cost-effective In Vivo and In Vitro Mouse Models for Evaluating Anticryptosporidial Drug Efficacy: Assessing Vorinostat, Docetaxel, and Baicalein.
Topics: Animals; Antiprotozoal Agents; Cost-Benefit Analysis; Cryptosporidiosis; Cryptosporidium; Cryptosporidium parvum; Docetaxel; Humans; Mice; Paromomycin; Plant Breeding; Vorinostat | 2023 |